UA researchers link liver disease, drug metabolism

News Release Date: 
Friday, June 26, 2015

Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications for people with type 2 diabetes. John Clarke, PhD, research associate, and Nathan Cherrington, PhD, professor, both of the college’s Department of Pharmacology and Toxicology, recently published a study in the journal Diabetes showing that a mouse model of obesity, diabetes and NASH retained the anti-diabetic drug metformin longer than a control group of healthy mice. The study, “Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis,” found that NASH can change the way drugs are eliminated from the body, potentially leading to toxic levels of metformin being retained in the body. Read More